AbbVie | ABBV - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
AbbVie USD 3.84B 205M 2026-09
Abbott USD 4.27B 669M 2026-09
ALKERMES USD 196.64M 67.96M 2026-06
Amgen USD 1.72B 134M 2026-06
AstraZeneca USD 4.07B 1.73B 2026-09
Biogen USD 752M 42.3M 2026-09
BioMarin Pharmaceutical USD 395.55M 137.27M 2026-06
Bristol-Myers Squibb USD 1.7B 127M 2026-09
Coherus Biosciences USD 15M 6.26M 2025-12
Eisai JPY 114.83B 4.71B 2026-06
Eli Lilly USD 3.12B 305M 2026-09
Gilead Sciences USD 1.52B 70M 2026-06
GlaxoSmithKline GBP 2.16B 39M 2026-09
J&J USD 6.25B 168M 2026-09
Medtronic 3.2B 141M 2026-06
Merck USD 2.86B 25M 2026-09
Neurocrine Biosciences USD 383.1M 64.6M 2026-06
Novartis USD 3.08B 163M 2026-09
Pacira USD 91.81M 7.93M 2026-06
Perrigo USD 3.28B 3.02B 2026-06
Pfizer USD 3.41B 496M 2026-06
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Roche Holding CHF 6.37B 908M 2026-06
Sanofi EUR 2.31B 325M 2026-09
UCB EUR 1.47B 193M 2025-12
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
United Therapeutics USD 206.7M 50.1M 2026-06
Vertex Pharmaceuticals USD 582.2M 88.5M 2026-06
Zoetis USD 592M 4M 2026-06